IPMNs, which may have distinct pathways to cancer progression [30], [31], [39], show an intriguing CSPG4 distinction between non-malignant and malignant entities; only the latter tend to up-regulate both pancreatic and circulating CSPG4 levels. The gene discussed is CSPG4; the disease is cancer.